February 12, 2024 · Form 4 insider transaction
VASCONCELLES MICHAEL sold 50,515 shares of ImmunoGen, Inc., a transaction worth N/A. The trade was recorded as disposition to the issuer and disclosed on an SEC Form 4, filed 0 days after the transaction.
Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time.